New Insights into Diabetic and Vision-Threatening Retinopathy: Importance of Plasma Long Pentraxine 3 and Taurine Levels

References

• Pusparajah P, Lee LH, Abdul Kadir K. Molecular markers of diabetic retinopathy: potential screening tool of the future? Front Physiol. 2016;7:200.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Cancarini A, dell’Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res. 2015;2015:582060.
   PubMed Web of Science ®Google Scholar
• Tomic M, Ljubic S, Kasˇtelan S, Antunica AG, Jazbec A, Polijicanin T. Inflammation, haemostatic disturbance, and obesity: possible link to pathogenesis of diabetic retinopathy in type 2 diabetes. Mediators In?amm. 2013;2013:818671.
   PubMed Web of Science ®Google Scholar
• Udaondo P, Hernandez C, Llort LB, Delpech S, Servat OS, Simo R. Usefulness of liquid biopsy biomarkers from aqueous humor in predicting anti-VEGF response in diabetic macular edema: results of a pilot study. J Clin Med. 2019;8:1841.
   PubMed Web of Science ®Google Scholar
• Niswender KD, Magnuson MA. Obesity and the beta cell: lessons from leptin. J Clin Invest. 2007;117:2753–56.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K. Determination of physiological plasma pentraxin 3 (PTX-3) levels in healthy populations. Clin Chem Lab Med. 2009;47:471–77.
   PubMed Web of Science ®Google Scholar
• Inoue K, Kodama T, Daida H. Pentraxin 3: A novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med. 2012;2012:657025.
   PubMedGoogle Scholar
• Sirdah MM. Protective and therapeutic effectiveness of taurine in diabetes mellitus: A rationale for antioxidant supplementation. Diabetes Metab Syndr. 2015;9:55–64.
   PubMed Web of Science ®Google Scholar
• Chen W, Guo J, Zhang Y, Zhang J. The beneficial effects of taurine in preventing metabolic syndrome. Food Funct. 2016;7:1849–63.
   PubMed Web of Science ®Google Scholar
• Nandhini AT, Thirunavukkarasu V, Ravichandran MK, Anuradha CV. Effect of taurine on biomarkers of oxidative stress in tissues of fructose-fed insulin-resistant rats. Singapore Med J. 2005;46:82–87.
   PubMedGoogle Scholar
• Pennathur S, Heinecke JW. Oxidative stress and endothelial dysfunction in vascular disease. Curr Diab Rep. 2007;7:257–64.
   PubMedGoogle Scholar
• Ulrich-Merzenich G, Zeitler H, Vetter H, Bhonde RR. Protective effects of taurine on endothelial cells impaired by high glucose and oxidized low density lipoproteins. Eur J Nutr. 2007;46:431–38.
   PubMed Web of Science ®Google Scholar
• Ripps H, Shen W. Review: taurine: A “very essential” amino acid. Mol Vis. 2012;18:2673–86.
   PubMed Web of Science ®Google Scholar
• Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44:260–77.
   PubMed Web of Science ®Google Scholar
• Ito T, Schaffer SW, Azuma J. The potential usefulness of taurine on diabetes mellitus and its complications. Amino Acids. 2012;42:1529–39.
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. Early Treatment Diabetic Retinopathy Study report number 10. Ophthalmology 1991;98::786–806.
   PubMed Web of Science ®Google Scholar
• Screening for diabetic retinopathy in Europe 15 years after the St. Vincent Declaration. Accessed 6 Oct 2015. http://reseauophdiat.aphp.fr/Document/Doc/confliverpool.pdf
   Google Scholar
• Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararaasegaram R, Verdaguar JT. Global diabetic retinopathy project group. proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–82.
   PubMed Web of Science ®Google Scholar
• Kinshuck D Examining and grading retinopathy, for professionals. Accessed 20 Aug 2015. http://www. diabeticretinopathy.org.uk/gradingretinopathy.html
   Google Scholar
• Chung YR, Kim YH, Ha SJ, Byeon HE, Cho CH, Kim JH, Lee K. Role of inflammation in classification of diabetic macular Edema by optical coherence tomography. J Diabetes Res. 2019;2019:8164250.
   PubMed Web of Science ®Google Scholar
• The Royal College of Ophthalmologists. Diabetic retinopathy guidelines. Accessed 6 Nov 2015. https://www. rcophth.ac.uk/wp-content/uploads/ 2014/12/2013-SCI301-FINAL-DR-GUIDELINES-DEC-2012-updatedJuly-2013.pdf
   Google Scholar
• Ciéslik P, Hrycek A. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications. Autoimmunity. 2012;45:119–28.
   PubMed Web of Science ®Google Scholar
• Casula M, Montecucco F, Bonaventura A, Liberale L, Veccihie A, Dallegri F, Carbone F. Update on the role of pentraxin 3 in atherosclerosis and cardiovascular diseases. Vascul Pharmacol. 2017;99:1–12.
   PubMed Web of Science ®Google Scholar
• Yang SE, Woo JE, Lee SJ, Park SH, Woo JM. Elevated plasma pentraxin 3 levels are associated with development and progression of diabetic retinopathy in Korean patients with type 2 diabetes mellitus. Invest Ophthalmol Vis Sci. 2014;55:5989–97.
   PubMed Web of Science ®Google Scholar
• Henderson AD, Bruce BB, Newman NJ, Hypertension-related Eye BV. Abnormalities and the risk of stroke. Rev Neurol Dis. 2011;8:1–9.
   PubMedGoogle Scholar
• Woo JM, Kwon MY, Shin DY, Kang YH, Hwang N, Chung SW. Human retinal pigment epithelial cells express the long pentraxin PTX3. Mol.Vis. 2013;19:303–10.
   PubMed Web of Science ®Google Scholar
• Nakabayashi S, Nagaoka T, Tani T, Sogawa K, Hein TW, Kuo L, Yoshida A. Retinal arteriolar responses to acute severe elevation in systemic blood pressure in cats: role of endothelium-derived factors. Exp Eye Res. 2012;103:63–70.
   PubMed Web of Science ®Google Scholar
• Rudnisky CJ, Wong BK, Virani H, Tennant MTS. Risk factors for progression of diabetic retinopathy in alberta first nations communities. Can J Ophthalmol. 2017;52:S19–S29.
   PubMed Web of Science ®Google Scholar
• Hu L, Li DH. Relationship between modified homeostasis model assessment/correlative serum factors and diabetic retinopathy among type 2 diabetics with insulin therapy in Guangzhou, China. Int J Ophthalmol. 2014;7:463–68.
   PubMed Web of Science ®Google Scholar
• Nakagami T, Takahasi K, Suto C, Oya J, Tanaka Y, Kurita M, Isago C, Hasegawa Y, Ito A, Uchigata Y. Diabetes diagnostic thresholds of the glycated hemoglobin A1c and fasting plasma glucose levels considering the 5-year incidence of retinopathy. Diabetes Res Clin Pract. 2017;124:20–29.
   PubMed Web of Science ®Google Scholar
• Cleland CR, Burton MJ, Hall C, Hall A, Courtright P, Makupa WU, Philippin H. Diabetic retinopathy in tanzania: prevalence and risk factors at entry into a regional screening programme. Trop Med Int Health. 2016;21:417–26.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Zhou F, Zhang Y, Zhou X, Ying C. Fasting plasma glucose variability levels and risk of adverse outcomes among patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2019;148:23–31.
   PubMed Web of Science ®Google Scholar
• Ripps H, Shen W. Review: taurine: A “very essential” amino acid. Mol Vis. 2012;18:2673–86.
   PubMed Web of Science ®Google Scholar
• Fan Y, Lai J, Yuan Y, Wang L, Wang Q, Yuan F. Taurine protects retinal cells and improves synaptic connections in early diabetic rats. Curr Eye Res. 2020;45:52–63.
   PubMed Web of Science ®Google Scholar
• Arfuzir NNN, Agarwal R, Iezhitsa I, Agarwal P, Sidek S, Ismail NM. Taurine protects against retinal and optic nerve damage induced by endothelin-1 in rats via antioxidant effects. Neural Regen Res. 2018;3(11):2014–2021.
   Google Scholar